My Website:	http://www.innovara.com/

About Me:	When a patient has a serious illness and there is no approved drug available, the physician may want to try one which has not been authorized for marketing by national health authorities but has shown promise in clinical trials. European Named Patient Programs, like US compassionate use programs, offer physicians access to pharmaceuticals which have not yet been licensed. However, there is one important difference: in Europe an unlicensed drug can be reimbursed. This presents drug-makers with an opportunity to generate revenues while development is still in-progress. Significant Revenues Are Possible The additional revenues can be considerable. For example, Pharmion, a US based company focusing on Oncology and Hematology reported dramatic increases in its Thalidomide sales from $1.9 million in 2Q '03 to $15.3 million in 2Q '04, primarily due to named patient sales in Europe for Multiple Myeloma. Thalidomide sales accounted for approximately 75% of Pharmion's total revenues for the first half of 2004, according to company sources, and were generated while the product awaits marketing approval for this indication. Before receiving European Marketing Approval, Shire's ArgylinÂ® for essential thrombocythaemia generated about 5% of its total sales from its European named patient program. http://www.innovara.com/training/pharmaceutical-training-development/pharmaceutical-sales-training-a-development-programs http://www.innovara.com/training/pharmaceutical-training-development http://www.innovara.com/

Galleries

Desktop Nexus

Tags of the Moment